Ernexa CEO says ERNA-101 aims to boost combination immunotherapy in solid tumors

ERNA•2026-07-24

ERNA-101 strategy and preclinical data

Ernexa management outlined a strategy to position ERNA-101 as a combination partner for immunotherapies by targeting the immunosuppressive tumor microenvironment.

Preclinical ovarian cancer data highlighted complete tumor elimination with PD-1 blockade, including independent validation showing durable clearance in about two-thirds of treated animals.

Development timeline and initial market focus

Manufacturing process development completed; engineering batch production started; IND submission targeted for Q3 2026.

Phase 1 first-in-human study anticipated in Q4 2026, with an initial commercial focus on about 15,000 annual U.S. platinum-resistant ovarian cancer diagnoses.

Ernexa CEO says ERNA-101 aims to boost combination immunotherapy in solid tumors

ERNA-101 strategy and preclinical data

Development timeline and initial market focus

Related News

Nasdaq trade halt <OMH.O> volatility trading pause at 10:00 AM

Provident Financial names CEO Donavon Ternes to board of directors

Nasdaq trade halt <BIOT.O> volatility trading pause at 09:32 am

Mexico's Televisa shares slide after second-quarter loss

US stocks-S&P 500, Nasdaq fall as investors juggle earnings, Mideast risks and tariffs